Pfizer

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

10 Jan 2025

C linically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would be the first

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

21 Dec 2024

BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal canc

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

19 Dec 2024

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpo

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

17 Dec 2024

Full-Year 2025 Revenue Guidance (1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted (2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted (2) Diluted EPS Operational

Pfizer Declares First-Quarter 2025 Dividend

13 Dec 2024

Board of Directors approves increase in quarterly cash dividend to $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash divide

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

12 Dec 2024

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy Pfizer Inc. (NYSE:

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

11 Dec 2024

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpo

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

11 Dec 2024

NEW HAVEN, Conn. and NEW YORK, December 10, 2024 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-stud

Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

06 Dec 2024

Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematology (ASH) Annual Meeting & Exposition (Decembe

Pfizer Announces New Chief Scientific Officer and President, Research & Development

20 Nov 2024

Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology

View details about the software product Informachine News Trackers